What is phenylpropanolamine used for

Because of continued reports to the fda of hemorrhagic stroke associated with phenylpropanolamine and the results of the yale study, we now feel that the risks of using ppa - phenylpropanolamine outweigh the benefits and recommend that consumers no longer use products containing ppa - phenylpropanolamine. 1. Is the medical service to be purchased prompted by a risky event, or is it the result of individual preference? 2. Is the price of transferring risk to a third party high or low? 3. Does the failure to obtain a service or the purchase of an inappropriate service potentially create costs for others in the pool? The first question relates to the terms under which people obtain health care services. People differ in their attitude toward medical care. They also differ in their aversion to risk. Take diagnostic tests for the detection of cancer. As we saw in the case of mammograms and Pap smears, the more frequent the tests, the higher the cost. Moreover, medical science cannot tell us how frequent such exams should be. That's a value judgment, and people's values differ. In general, such exams are not prompted by a risky event. They are determined instead by individual preferences. As a general rule, the more expenditures depend on personal choices rather than external events, the greater will be the problem of moral hazard and the more persuasive will be the purchase of services whose cost exceeds their value to the patient. This consideration suggests we should encourage individuals to purchase directly most diagnostic tests and most forms of preventive medicine. The second question reinforces this conclusion. Transferring the risk of cancer treatment to an insurance pool is relatively low cost. For each dollar of exposure transferred, the extra premium is only a few pennies. On the other hand, transferring diagnostic testing to an insurance pool is relatively high cost. For each dollar of exposure transferred, the extra premium is a large part of a dollar. So the payoff for using insurance to cover cancer treatment is high, while the payoff for covering cancer detection is low. The third question is whether the medical consequences of one's decision will generate costs for other members of the pool. Take immunization for childhood diseases. As we saw above, studies show that these procedures pay for themselves by avoiding future health care costs that are greater than the costs of the vaccinations. This implies that members of an insurance pool have an economic self-interest in seeing that all children covered by the pool are vaccinated. It may make economic sense for the pool to pay for vaccinations, thereby incurring more cost than self-pay would generate, or to require that members obtain them, thereby reducing autonomy. Closely related to the problem created by the failure to obtain a desirable service is the problem created by the purchase of the wrong service. Suppose our plan has a , 000 deductible and a member is diagnosed with cancer. Under this arrangement, the patient would pay the first , 000 of treatment costs and presumably would make his or her own decisions about how to spend the , 000. But that , 000 of decision making could have a large impact on later treatment costs, and bad decisions early on could generate larger subsequent costs for the group. Such considerations may create a presumption in favor of paying for all treatment costs from the pool in cases where the entire treatment regime promises to be expensive. Click here to see Table XII Table XII summarizes the case for a division between individual payment for medical services and third-party payment. Third-party payment for every medical service is potentially very wasteful. Such waste can be ameliorated only by invasive, expensive third-party oversight Page 74.

Vol 3 January 2004 total of 1200 patients 2 ; taking opioids on a regular scale for pain therapy. In addition, re-examining a total of 11, 882 patients psychological dependency could only be observed in 4 cases which amounts to an incidence of 0, 03% 4 ; . Also, psychological dependency could not be demonstrated using an opioid in the longterm therapy for pain of nonmalignant origin 5, 6 ; . This is conceivable because the controlled release formulation of opioids makes the development of psychological dependency impossible since sudden increase in peak plasma levels is not seen, otherwise a prerequisite to induce an "opioid-high". Also, all research studies point out that the sole opioid intake is not the only factor leading to the development of dependency. Other, more important factors, like social surroundings and the basic personality structure have a much more important impact on the development of dependency 7 ; . In addition, re-examining the incidence of tolerance development after intake of potent morphinomimetics have clearly shown, that the abuse of analgesics of nonopioid structure or the combination of a weak opioid with a peripheral analgesic is found more often in dependent than in nondependent patients 8, 9 ; . On the other hand, contrary to psychological, physical dependency will develop within any long lasting therapy with opioids. This however, does not justify reducing the dose or completely abolishing the use of an opioid. Prescribing controlled substances for legitimative medical use requires special caution because of their potential for abuse and dependence. It therefore is indispensary for the prescribing physician to identify the subject with signs of potential abuse problems. The following characteristic behavioral pattern is seen in drug diverters: 1. Strange stories surrounding why they need prescription medication. 2. Subjects demonstrate a reluctance to cooperate. 3. There is an unusual high or low 7.
Later. The final titer of the virus was ; 109 or 108 colony-forming units ml for pMy or pGpig, respectively and pima.

Phenylpropanolamine disudrin drug study